ADP 31415

Drug Profile

ADP 31415

Alternative Names: ADP31415

Latest Information Update: 15 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Almirall S.A.
  • Class Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pemphigus vulgaris

Most Recent Events

  • 07 Nov 2016 Phase-I clinical trials in Pemphigus vulgaris in Spain
  • 24 Jul 2015 Preclinical trials in Pemphigus vulgaris in Spain (unspecified route) (Almirall's pipeline, July 2015)
  • 26 Jan 2015 ADP 31415 - Almirall receives Orphan Drug status for Pemphigus vulgaris in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top